Aurinia/3SBio Inc. Drug Effective Against Lupus Nephritis

Canada's Aurinia Pharma reported Luveniq (voclosporin), a potential treatment for lupus nephritis, produced positive data in early results from a Phase IIb trial, currently underway in Malaysia. 3SBio licensed China rights to the drug in 2010. Out of 7 patients with the disease, there were four with complete remission at week eight and a mean reduction in proteinuria (abnormal quantities of protein in urine) of 72%, also at week eight. Complete results of the trial are expected in Q3 of 2016.

Back to news